Company Profiles

driven by the PitchBook Platform

Apofore

Description

Developer of novel therapeutics designed to treat Type 2 diabetes. The company's novel therapeutics use naturally occurring protein, Apolipoprotein A-IV (apo A-IV) as an important regulator of insulin secretion and glucose homeostasis, enabling patients to reduce blood sugar and increase insulin secretion.

2011

Founded

OOB

Status

Out of Business

Latest Deal Type

$500k

Total Amount Raised

Description

Developer of novel therapeutics designed to treat Type 2 diabetes. The company's novel therapeutics use naturally occurring protein, Apolipoprotein A-IV (apo A-IV) as an important regulator of insulin secretion and glucose homeostasis, enabling patients to reduce blood sugar and increase insulin secretion.

Website:

www.apofore.com

Ownership Status

Out of Business

Financing Status

Formerly VC-Backed

Primary Industry

Pharmaceuticals

Other Industries

Therapeutic Devices

Primary Office

55 Cambridge Parkway Suite 102 Cambridge, MA 02142United States
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Apofore's full profile, request a free trial.

    Apofore Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Apofore Executive Team (1)

    NameTitleBoard
    Seat
    Contact
    Info
    Patrick Tso Ph.DScientific Founder
    Patrick Tso Ph.D Scientific Founder

    Apofore Board Members (1)

    NameRepresentingRoleSinceContact
    Info
    Mark O'MahonySelfBoard Member000 0000
    Mark O'Mahony Board Member Self
    Request full access to PitchBook